{"id":6270,"date":"2023-11-09T15:29:57","date_gmt":"2023-11-09T20:29:57","guid":{"rendered":"https:\/\/www.wmfc.ca\/?p=6270"},"modified":"2023-11-09T15:29:57","modified_gmt":"2023-11-09T20:29:57","slug":"2023-conference-de-la-societe-americaine-dhematologie","status":"publish","type":"post","link":"https:\/\/www.wmfc.ca\/fr\/2023\/11\/09\/2023-american-society-of-hematology-conference\/","title":{"rendered":"Conf\u00e9rence 2023 de la Soci\u00e9t\u00e9 am\u00e9ricaine d'h\u00e9matologie"},"content":{"rendered":"<p>This time of year, the presentations at the ASH (American Society of Hematology) Conference become available.\u00a0 Remembering that conference presentations do not go through a full peer review (unlike journal articles), they do give us an idea of what research is being done, and what kinds of results are being seen.<\/p>\n<p>You can access 75 <a href=\"https:\/\/ash.confex.com\/ash\/2023\/webprogram\/start.html#srch=words%7Cmacroglobulinemia%7Cmethod%7Cand%7Cpge%7C1%7CbyDayany%7Cany%7CbySymposiumany%7Cany%7CbyAudienceany%7Cany\" target=\"_blank\" rel=\"noopener\">items that mention the word &#8220;macroglobulinemia&#8221;, here<\/a>.\u00a0 We&#8217;re not suggesting you investigate all of them, but they are certainly available for your perusal.<\/p>\n<p>There are three in particular, though, that you may find of note.<\/p>\n<p><a href=\"https:\/\/ash.confex.com\/ash\/2023\/webprogram\/Paper186347.html\" target=\"_blank\" rel=\"noopener\">This paper<\/a> is an interim report on our Canadian <a href=\"https:\/\/www.wmfc.ca\/2022\/03\/13\/brawm-trial-update-from-dr-neil-berinstein\/\">BRAWM trial, headed up by Dr. Berinstein<\/a>.\u00a0 The one-sentence Conclusion section sums it up: &#8220;Bendamustine, rituximab and acalabrutinib front-line therapy for WM is safe and well tolerated and initial clinical results show that this treatment induces a high percentage of CR + VGPRs&#8221;.<\/p>\n<p><a href=\"https:\/\/ash.confex.com\/ash\/2023\/webprogram\/Paper181925.html\" target=\"_blank\" rel=\"noopener\">Many patients<\/a> are resorting to dose reductions of Ibrutinib to manage adverse side effects.\u00a0 This paper reports on somewhat limited, but real-world data following dose reductions of Ibrutinib.\u00a0 From the conclusions, &#8220;&#8230; ibrutinib DR [Dose Reduction] can be an effective strategy to manage AEs [Adverse Events] while maintaining clinical efficacy&#8221;.<\/p>\n<p><a href=\"https:\/\/ash.confex.com\/ash\/2023\/webprogram\/Paper174294.html\" target=\"_blank\" rel=\"noopener\">Other patients<\/a> are transitioning from ibrutinib to zanubrutinib, because of side-effects.\u00a0 This paper reports data from such patients a year or more after transitioning to zanubrutinib.\u00a0 From the conclusions, &#8220;While limited by sample size and nonrandomized\/<em>ad hoc<\/em> analysis, data suggest that patients may transition from ibrutinib to zanubrutinib without compromising safety or efficacy; long-term follow-up is ongoing&#8221;.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>This time of year, the presentations at the ASH (American Society of Hematology) Conference become available.\u00a0 Remembering that conference presentations do not go through a full peer review (unlike journal articles), they do give us an idea of what research is being done, and what kinds of results are being seen. You can access 75 items that mention the word &#8220;macroglobulinemia&#8221;, here.\u00a0 We&#8217;re not suggesting you investigate all of them, but they are certainly available for your perusal. There are three in particular, though, that you may find of note. This paper is an interim report on our Canadian BRAWM trial, <a href=\"https:\/\/www.wmfc.ca\/fr\/2023\/11\/09\/2023-american-society-of-hematology-conference\/\"> [&#8230;]<\/a><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_price":"","_stock":"","_tribe_ticket_header":"","_tribe_default_ticket_provider":"","_ticket_start_date":"","_ticket_end_date":"","_tribe_ticket_show_description":"","_tribe_ticket_show_not_going":false,"_tribe_ticket_use_global_stock":"","_tribe_ticket_global_stock_level":"","_global_stock_mode":"","_global_stock_cap":"","_tribe_rsvp_for_event":"","_tribe_ticket_going_count":"","_tribe_ticket_not_going_count":"","_tribe_tickets_list":"[]","_tribe_ticket_has_attendee_info_fields":false,"footnotes":""},"categories":[20],"tags":[],"class_list":["post-6270","post","type-post","status-publish","format-standard","hentry","category-news"],"_links":{"self":[{"href":"https:\/\/www.wmfc.ca\/fr\/wp-json\/wp\/v2\/posts\/6270","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.wmfc.ca\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.wmfc.ca\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.wmfc.ca\/fr\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.wmfc.ca\/fr\/wp-json\/wp\/v2\/comments?post=6270"}],"version-history":[{"count":5,"href":"https:\/\/www.wmfc.ca\/fr\/wp-json\/wp\/v2\/posts\/6270\/revisions"}],"predecessor-version":[{"id":6275,"href":"https:\/\/www.wmfc.ca\/fr\/wp-json\/wp\/v2\/posts\/6270\/revisions\/6275"}],"wp:attachment":[{"href":"https:\/\/www.wmfc.ca\/fr\/wp-json\/wp\/v2\/media?parent=6270"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.wmfc.ca\/fr\/wp-json\/wp\/v2\/categories?post=6270"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.wmfc.ca\/fr\/wp-json\/wp\/v2\/tags?post=6270"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}